Independent
Tenure on this board
4.7 yrs
Also a director at
Curis Inc (CRIS)
2 nominees · 4 ballot items.
Four proposals: (1) Elect two Class I directors (Anne Borgman, M.D. and John G. Houston, Ph.D.); (2) Ratify Ernst & Young LLP as independent registered public accounting firm for 2026; (3) Advisory (non-binding) vote to approve executive compensation (“Say-on-Pay”); and (4) Approve an amendment and restatement of the 2019 Omnibus Incentive Plan to, among other items, increase the number of shares authorized for issuance thereunder.
Elect Anne Borgman, M.D. and John G. Houston, Ph.D. as Class I directors, each to serve three-year terms expiring in 2029.
Ratify the audit committee’s appointment of Ernst & Young LLP as NextCure’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Non-binding, advisory vote to approve the compensation paid to the Company’s named executive officers as disclosed in the proxy statement.
This non-binding management proposal asks stockholders to approve, on an advisory basis, the Company’s disclosed compensation for its named executive officers. Management frames the program as a mix of base salary, annual cash incentive and long-term equity awards intended to attract and retain key executives while aligning their incentives with stockholder interests and strategic goals. The compensation committee used third‑party benchmarking and engaged an independent consultant to inform target pay and incentive structures, and the Board emphasizes pay-for-performance by tying cash incentives and equity vesting to corporate and operational milestones. The Board also notes that the advisory vote is non-binding and that it will consider the vote’s outcome when making future compensation decisions, signaling responsiveness without legally mandated change. Governance context includes the Company’s smaller reporting company status, recent equity grants, and a compensation clawback policy and other controls intended to limit excessive risk-taking. The Board recommends approval because it believes the current program balances retention needs, performance alignment, and prudent risk management, and because rejecting the proposal would not automatically change compensation but would prompt further review by the Board and compensation committee. Potential stockholder concerns include perceived pay levels during clinical-stage development, dilution from equity awards, and the effective influence of a non-binding vote; management addresses these by explaining the structure, benchmarking, and discretion retained by the Board. Overall, the proposal is a governance-focused ask that gives stockholders a voice on pay while preserving Board authority to manage compensation programs.
Approve the Amended and Restated 2019 Omnibus Incentive Plan to increase the number of shares available for issuance (requesting an additional 80,000 shares), amend the evergreen provision to use fully diluted shares (including prefunded warrants), increase the incentive stock option limit, and make administrative updates to support recruiting, retention and long-term incentives.
This management proposal seeks shareholder approval to amend and restate the 2019 Omnibus Incentive Plan primarily to add 80,000 shares to the plan reserve and to modify the annual evergreen increase to be based on fully diluted shares (including prefunded warrants). Management argues the change is needed because only 80,117 shares remained available as of April 22, 2026 and continued equity awards are a key tool for recruiting, motivating and retaining employees, officers, consultants and non‑employee directors in a competitive biotech labor market. The filing quantifies plan metrics: current overhang of approximately 29.8% (20.3% including pre-funded warrants), a three‑year average burn rate around 7.5% (4.2% in 2025), and that adding 80,000 shares would produce an aggregate overhang near 32.0% (21.8% including pre-funded warrants), with a post-approval reserve of 160,117 shares. The Board highlights that without additional share capacity the Company may have to raise the cash component of compensation, which could be counterproductive to aligning employee interests with stockholders. The proposal also increases the incentive stock option cap and clarifies administrative and change-in-control provisions; the committee retains discretion over grants and anti‑repricing protections remain in place without stockholder approval. From a governance perspective, shareholders face trade-offs: dilution risk from an expanded reserve versus the operational risk of being unable to grant equity needed to advance clinical programs and retain talent. The Board recommends FOR, citing competitive necessity, controlled historical usage of equity, and mechanisms in the plan that limit repricing and require stockholder approval for certain changes; sophisticated investors should weigh the incremental dilution against the Company’s stage, burn rate, and talent needs.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Squadron Capital Management LLC | 7.34% | 265,000 | $3M |
| 2 | Affinity Asset Advisors, LLC | 6.69% | 241,826 | $3M |
| 3 | Ikarian Capital, LLC | 6.60% | 238,303 | $3M |
| 4 | Sofinnova Investments, Inc. | 6.16% | 222,654 | $2M |
| 5 | SILVERARC CAPITAL MANAGEMENT, LLC | 4.87% | 176,057 | $2M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.44% | 160,473 | $2M |
| 7 | PFIZER INC | 4.25% | 153,354 | $2M |
| 8 | Opaleye Management Inc. | 3.91% | 141,181 | $2M |
| 9 | AWM Investment Company, Inc.Activist | 3.25% | 117,371 | $1M |
| 10 | Exome Asset Management LLC | 3.20% | 115,500 | $1M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.